- Home
- ADPT vs ARVN Comparison
ADPT vs ARVN Comparison
Compare ADPT & ARVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ADPT
- ARVN
- Stock Information
- Founded
- ADPT 2009
- ARVN 2015
- Country
- ADPT United States
- ARVN United States
- Employees
- ADPT N/A
- ARVN N/A
- Industry
- ADPT Biotechnology: Biological Products (No Diagnostic Substances)
- ARVN Biotechnology: Pharmaceutical Preparations
- Sector
- ADPT Health Care
- ARVN Health Care
- Exchange
- ADPT Nasdaq
- ARVN Nasdaq
- Market Cap
- ADPT 1.2B
- ARVN 1.4B
- IPO Year
- ADPT 2019
- ARVN 2018
- Fundamental
- Price
- ADPT $8.27
- ARVN $17.77
- Analyst Decision
- ADPT Buy
- ARVN Strong Buy
- Analyst Count
- ADPT 5
- ARVN 12
- Target Price
- ADPT $9.10
- ARVN $58.82
- AVG Volume (30 Days)
- ADPT 1.4M
- ARVN 1.0M
- Earning Date
- ADPT 02-11-2025
- ARVN 02-11-2025
- Dividend Yield
- ADPT N/A
- ARVN N/A
- EPS Growth
- ADPT N/A
- ARVN N/A
- EPS
- ADPT N/A
- ARVN N/A
- Revenue
- ADPT $178,957,000.00
- ARVN $263,399,999.00
- Revenue This Year
- ADPT $20.07
- ARVN N/A
- Revenue Next Year
- ADPT $25.27
- ARVN $1.63
- P/E Ratio
- ADPT N/A
- ARVN N/A
- Revenue Growth
- ADPT 5.10
- ARVN 235.54
- 52 Week Low
- ADPT $2.28
- ARVN $16.61
- 52 Week High
- ADPT $8.95
- ARVN $51.51
- Technical
- Relative Strength Index (RSI)
- ADPT 58.94
- ARVN 44.33
- Support Level
- ADPT $8.09
- ARVN $17.19
- Resistance Level
- ADPT $8.69
- ARVN $20.38
- Average True Range (ATR)
- ADPT 0.64
- ARVN 1.38
- MACD
- ADPT -0.00
- ARVN 0.08
- Stochastic Oscillator
- ADPT 65.66
- ARVN 30.77
About ADPT Adaptive Biotechnologies Corporation
Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers, including diffuse large B-cell lymphoma (DLBCL).
About ARVN Arvinas Inc.
Arvinas Inc is a United States-based biopharmaceutical company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development and commercialization of therapies that degrade disease-causing proteins.. The company's proprietary Proteolysis-Targeting Chimera (PROTAC), work by inducing the cell's own ubiquitin-proteasome system to target, degrade and remove disease-causing proteins. The group's product candidates are bavdegalutamide, ARV-471 and ARV-766.